Mainstream

Y-mAbs Therapeutics beats top-line and bottom-line estimates; initiates Q2 and reaffirms FY outlook

Y-mAbs Therapeutics beats top-line and bottom-line estimates; initiates Q2 and reaffirms FY outlook

Post ContentymabRead More

You might also be interested in reading OpenAI rolls out deep research AI agent to various users.

May 13, 2025
In Mainstream